Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    Revision: v3.3.2 has been added and Revision: v3.3.1 has been removed.
    Difference
    0.0%
    Check dated 2025-11-28T04:27:59.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision tag updated from v3.2.0 to v3.3.1; no changes to trial details, outcomes, eligibility criteria, or locations.
    Difference
    0.0%
    Check dated 2025-11-21T02:11:18.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The funding status notice about government operations was removed from the page. This notice previously warned that updates may be delayed due to appropriations.
    Difference
    0.2%
    Check dated 2025-11-13T22:49:41.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    No additions or deletions affecting core page content were detected; the study overview and eligibility details appear unchanged.
    Difference
    0.2%
    Check dated 2025-10-30T15:23:01.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Major update to core content with a funding-status notice and a version upgrade from v3.0.2 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-02T01:17:43.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Version bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-30T14:33:03.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.